Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,590 across all filing types
Latest filing 2026-03-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
章程修正案
Board/Management Information Classification · 95% confidence The document is a formal announcement regarding amendments to the company's articles of association (公司章程) due to changes in registered capital and share capital following stock incentive exercises. It details specific changes to the articles and mentions that the amendments require shareholder approval and regulatory filing. The document is not a full report but an announcement of governance changes related to board decisions and capital structure reflected in the articles. This fits best under Board/Management Information (MANG) as it involves board resolutions and governance amendments, not a full capital change announcement (SHA) or a report publication. The document length is short and focused on governance changes.
2026-03-23 Chinese
关于变更公司注册资本及修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from a company about changes to its registered capital and amendments to its Articles of Association (公司章程). It details the increase in registered capital due to stock options exercised and the corresponding revisions to the company's charter. The document is relatively short (1110 characters) and serves as a formal public notice of these changes. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is not a report publication announcement since it contains substantive content about the capital change and charter amendment. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2026-03-23 Chinese
关于向商业银行申请集团综合授信额度并对子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding its application for a comprehensive credit facility from commercial banks and the provision of guarantees to its subsidiaries. It includes details about the credit limit, guarantee amounts, company and subsidiary information, and board approval. The document does not contain financial statements or detailed financial performance data but is a formal disclosure of financing arrangements and guarantees. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or AGM material. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and credit facilities.
2026-03-23 Chinese
关于2025年度募集资金存放、管理与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled "2025 年度募集资金存放、管理与使用情况的专项报告" which translates to "2025 Annual Report on the Deposit, Management and Use of Raised Funds." It details the amounts raised through various financing activities (convertible bonds, private placements, and specific stock issuances), the management and storage of these funds in special accounts, usage of the funds including investment projects, changes in fund usage, and compliance with regulatory requirements. The document includes detailed financial tables and audit verification references, indicating it is a comprehensive report on fundraising capital management and usage for the fiscal year 2025. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters), contains substantive financial data, and is not merely an announcement or certification. Therefore, the appropriate classification is CAP.
2026-03-23 Chinese
东莞证券股份有限公司关于特一药业集团股份有限公司2025年度募集资金存放、管理与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Dongguan Securities Co., Ltd., acting as the sponsor institution, regarding the special audit opinion on the deposit, management, and use of raised funds by Te Yi Pharmaceutical Group Co., Ltd. for the fiscal year 2025. It references regulatory frameworks such as the Securities Law, Shenzhen Stock Exchange listing rules, and includes detailed financial data on fundraising amounts, usage, bank accounts, agreements, and audit opinions from a certified accounting firm. The document contains extensive financial tables and explanations about the use and management of funds raised through convertible bonds and private placements. It is not a brief announcement or a certification letter but a comprehensive audit and management report on fundraising activities and fund usage. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to fundraising and fund management, excluding full annual reports. The document is too detailed and lengthy to be a simple announcement or regulatory filing, and it is not an annual or interim financial report, nor a capital update or earnings release. Therefore, the most appropriate classification is AR (Audit Report / Information).
2026-03-23 Chinese
2025年度独立董事述职报告（赵晓波）
Board/Management Information Classification · 95% confidence The document is titled as an independent director's work report for the year 2025, detailing the director's attendance at board and shareholder meetings, committee participation, supervision of company governance, and protection of shareholder rights. It is a narrative report on the director's duties and activities rather than a financial report or announcement. The content focuses on governance and oversight rather than financial results or regulatory filings. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2026-03-23 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.